Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
India
/
Pharmaceuticals & Biotech
/
Granules India
532482
Granules India
Peptide CDMO Overcapacity And Debt Will Undermine Performance
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
24 Aug 25
Updated
24 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹480.00
2.2% undervalued
intrinsic discount
24 Aug
₹469.55
1Y
-30.3%
7D
2.8%
Loading
1Y
-30.3%
7D
2.8%
Author's Valuation
₹480.0
2.2% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹480.0
2.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
69b
2014
2017
2020
2023
2025
2026
2028
Revenue ₹69.2b
Earnings ₹9.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.35%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹9.10b
Earnings '28
x
18.37x
PE Ratio '28
=
₹167.09b
Market Cap '28
₹167.09b
Market Cap '28
/
243.57m
No. shares '28
=
₹686.01
Share Price '28
₹686.01
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹478.89
Fair Value '25
